 |
市场调查报告书
商品编码
1983324
癌症精准医疗市场：按组成部分、诊疗路径阶段、技术、生物标记类型、检体类型、最终用户、癌症类型、报销及获取管道以及地区划分Oncology Precision Medicine Market, By Component, By Care Pathway Stage, By Technology, By Biomarker Type, By Sample Type, End User, By Cancer Type, By Reimbursement & Access Channel, By Geography |
||||||
价格
简介目录
预计到2026年，癌症精准医疗市场规模将达到1,905亿美元，到2033年将达到3,665.3亿美元。预计从2026年到2033年，该市场将以9.8%的复合年增长率成长。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 1905亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2026年至2033年 |
| 2026年至2033年预测期间的复合年增长率： | 9.80% | 2033年市场规模预测： | 3665.3亿美元 |
全球癌症精准医疗市场代表着癌症治疗领域的突破性模式转移，从根本上改变了医疗专业人员进行诊断、选择治疗方法和患者照护管理的方式。肿瘤精准医疗利用先进的基因测序、生物标记识别、分子诊断和人工智慧技术，提供高度个人化的治疗性介入根据患者的个别特征和特定肿瘤特征量身定制。
这种创新方法超越了传统的、统一的调查方法，使临床医生能够根据每位患者特有的恶性肿瘤的基因突变、蛋白质表现和细胞路径，确定最佳治疗方案。次世代定序(NGS)、液态生物检体、药物基因体学和伴随诊断等最尖端科技的整合，正在加速标靶治疗治疗、免疫疗法和联合疗法的开发，这些通讯协定展现出卓越的疗效和更低的副作用。随着全球医疗保健系统日益采用基于价值的医疗模式，并致力于在控製成本的同时改善患者预后，精准医疗正成为一项关键解决方案，有望提高治疗反应率，最大限度地减少试验错处方笺，并最终提高包括肺癌、乳癌、结直肠癌、黑色素瘤和骨髓恶性肿瘤在内的多种癌症的生存率。
市场动态
全球癌症精准医疗市场受到多项强劲市场驱动因素的推动，这些因素持续加速市场扩张，并促进全球医疗机构的普及应用。其中一个关键成长要素是基因测序技术成本的快速下降。这使得精准诊断在常规临床实践中更容易取得，也更经济可行；同时，全球癌症发生率的上升也催生了对更有效、更个人化治疗方案的迫切需求。
人工智慧、机器学习演算法和巨量资料分析等领域的技术进步，使医疗服务提供者能够处理大量的基因组和临床数据，从而实现更精准的治疗预测和药物选择。政府倡议、监管支持以及公私合作对精准医疗研究的大量投资，进一步加速了市场成长，例如美国食品药物管理局（FDA）等机构正在简化伴随诊断和标靶治疗的核准流程。
然而，该市场面临许多限制因素，尤其是在发展中地区建设医疗设施的高昂成本、各国法规结构的复杂性以及有效利用精准医疗技术所需的专业基础设施和训练有素的人员。此外，对资料隐私的担忧、基因检测相关的伦理考量以及某些医疗体系报销政策的限制也阻碍了市场渗透。
儘管如此，将精准医疗融入常规临床工作流程的潜力正在涌现出巨大的机会，尤其是在其应用扩展到罕见癌症、液态生物检体技术更加普及、与製药公司在生物标誌物主导的药物发现方面合作增多，以及医疗保健数位化加速发展、个性化疗法成为全球肿瘤学标准治疗方案的情况下。
本报告的主要特点
- 本报告对全球癌症精准医疗市场进行了详细分析，包括预测期（2026-2033 年）的市场规模和复合年增长率，以 2025 年为基准年。
- 此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
- 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本文根据以下参数，介绍了全球癌症精准医疗市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
- 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
- 《全球癌症精准医疗市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球癌症精准医疗市场中使用的各种策略矩阵来促进决策。
目录
第一章：分析目标与假设
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章：市场动态、监管与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 法规环境
- 产品上市及核准
- PEST分析
- 波特五力分析
- 市场机会
- 法规环境
- 主要进展
- 产业趋势
第四章：全球癌症精准医疗市场：按组成部分划分（2021-2033 年）
- 治疗药物
- 诊断/检查
- 资讯学与决策支持
- 服务
第五章：全球癌症精准医疗市场：依治疗路径阶段划分（2021-2033 年）
- 风险评估和筛检
- 诊断和肿瘤分类
- 治疗方法方案
- 治疗监测
- 復发监测/微小残留病灶（MRD）
- 临床试验的註册和匹配
第六章：全球癌症精准医疗市场：依技术划分（2021-2033 年）
- 基因组学
- 次世代定序（NGS）
- 转录组学
- 蛋白质体学/蛋白质生物标记物
- 细胞遗传学和结构突变
- 表观遗传学
- 液态生物检体技术
- 单细胞空间分析
第七章 全球癌症精准医疗市场：依生物标记类型划分（2021-2033 年）
- 基因生物标记
- 基因组特征/全域标记
- 表现/蛋白质标记物
- 表观遗传生物标记
- MRD生物标记
第八章 全球癌症精准医疗市场：依检体类型划分（2021-2033 年）
- 组织起源
- 血液来源（液态生物检体）
- 其他生物体液
- 细胞学检体
第九章 全球癌症精准医疗市场：依最终用户划分（2021-2033 年）
- 医院和癌症中心
- 诊断检查室
- 临床病理检查室
- 分子和基因检查室
- 学术和研究机构
- 製药和生物技术公司
- CRO/临床试验网络
- 保险公司/HTA代理机构
第十章：全球癌症精准医疗市场：依癌症类型划分（2021-2033 年）
- 固体癌
- 肺、乳房、大肠、摄护腺、卵巢、黑色素瘤、胰臟、胃、头颈部、肝臟、肾臟、脑部/中枢神经系统等。
- 骨髓恶性肿瘤
- 白血病、淋巴瘤、多发性骨髓瘤、MDS/MPN 等。
- 罕见癌症/肿瘤- 特异性片段
- 由肿瘤特异性生物标记定义的族群
第十一章 全球癌症精准医疗市场：按报销和取得管道划分（2021-2033 年）
- 公共保险报销
- 私人保险报销
- 自费/自筹资金
- 混合保险模式
- 病人支持/服务项目
- 透过临床试验进行的测试
第十二章 全球癌症精准医疗市场：依地区划分（2021-2033年），市场规模
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第十三章 竞争格局
- Hoffmann La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck &Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc
第十四章 分析师建议
- 机会
- 分析师意见
- Coherent Opportunity Map (COM)
第十五章 参考文献与分析方法
- 参考
- 分析方法
- 关于 Coherent Market Insights
简介目录
Product Code: CMI9316
Oncology Precision Medicine Market is estimated to be valued at USD 190.50 Bn in 2026 and is expected to reach USD 366.53 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 190.50 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 366.53 Bn |
The global oncology precision medicine market represents a revolutionary paradigm shift in cancer treatment, fundamentally transforming how healthcare providers approach diagnosis, treatment selection, and patient care management. Precision medicine in oncology leverages advanced genomic sequencing, biomarker identification, molecular diagnostics, and artificial intelligence to deliver highly personalized therapeutic interventions tailored to individual patient profiles and specific tumor characteristics.
This innovative approach moves beyond the traditional one-size-fits-all treatment methodology, enabling clinicians to identify optimal therapeutic pathways based on genetic mutations, protein expressions, and cellular pathways unique to each patient's malignancy. The integration of cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsies, pharmacogenomics, and companion diagnostics has accelerated the development of targeted therapies, immunotherapies, and combination treatment protocols that demonstrate superior efficacy rates and reduced adverse effects. As healthcare systems worldwide increasingly adopt value-based care models and seek to improve patient outcomes while managing costs, precision medicine emerges as a critical solution that promises to enhance treatment response rates, minimize trial-and-error prescribing, and ultimately improve survival rates across various cancer types including lung, breast, colorectal, melanoma, and hematological malignancies.
Market Dynamics
The global oncology precision medicine market is propelled by several compelling drivers that continue to accelerate market expansion and adoption rates across healthcare institutions worldwide. The primary growth driver stems from the rapidly declining costs of genomic sequencing technologies, making precision diagnostics more accessible and economically viable for routine clinical implementation, while simultaneously increasing cancer incidence rates globally create an urgent demand for more effective, personalized treatment solutions.
Technological advancements in artificial intelligence, machine learning algorithms, and big data analytics enable healthcare providers to process vast amounts of genomic and clinical data, facilitating more accurate treatment predictions and drug selection processes. Government initiatives, regulatory support, and substantial investments in precision medicine research from both public and private sectors further accelerate market growth, with organizations like the U.S. FDA streamlining approval processes for companion diagnostics and targeted therapies.
However, the market faces significant restraints including high implementation costs for healthcare facilities, particularly in developing regions, complex regulatory frameworks that vary across different countries, and the need for specialized infrastructure and trained personnel to effectively utilize precision medicine technologies. Data privacy concerns, ethical considerations surrounding genetic testing, and limited reimbursement policies in certain healthcare systems also impede market penetration.
Nevertheless, substantial opportunities emerge from expanding applications in rare cancers, growing adoption of liquid biopsy technologies, increasing pharmaceutical partnerships for biomarker-driven drug development, and the potential for precision medicine integration into routine clinical workflows, particularly as healthcare digitization accelerates and personalized treatment becomes the standard of care across oncology practices globally.
Key Features of the Study
- This report provides in-depth analysis of the global oncology precision medicine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oncology precision medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann La Roche Ltd, Novartis AG, Pfizer Inc, AstraZeneca plc, Bristol Myers Squibb Company, Merck & Co Inc, Gilead Sciences Inc, Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN NV, BioNTech SE, Amgen Inc, Foundation Medicine Inc, Guardant Health, and Myriad Genetics Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global oncology precision medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology precision medicine market
Market Segmentation
- Component Insights (Revenue, USD Bn, 2021 - 2033)
- Therapeutics
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
- Care Pathway Stage (Revenue, USD Bn, 2021 - 2033)
- Risk assessment & screening
- Diagnosis & tumor classification
- Therapy selection
- Treatment monitoring
- Response monitoring
- Resistance emergence detection
- Dose/therapy optimization
- Recurrence surveillance / MRD
- Clinical trial enrolment & matching
- Technology (Revenue, USD Bn, 2021 - 2033)
- Genomics
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
- Biomarker Type (Revenue, USD Bn, 2021 - 2033)
- Genetic biomarkers
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic signatures / global markers
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / protein markers
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic biomarkers
- Methylation signatures
- MRD biomarkers
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
- Sample Type (Revenue, USD Bn, 2021 - 2033)
- Tissue-based
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other biofluids
- Urine, saliva, CSF (indication-dependent)
- Cytology samples
- FNA, smears (select workflows)
- End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals & cancer centers
- Diagnostic laboratories
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Pharmaceutical & biotech companies
- CROs / clinical trial networks
- Payers / HTA bodies
- Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Solid tumors
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic malignancies
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare cancers / tumor-agnostic segments
- Tumor-agnostic biomarker-defined populations
- Reimbursement & Access Channel (Revenue, USD Bn, 2021 - 2033)
- Public reimbursement
- Private reimbursement
- Out-of-pocket / self-pay
- Hybrid coverage models
- Patient assistance / access programs
- Clinical trial-funded testing
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck & Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Oncology Precision Medicine Market, By Component
- Global Oncology Precision Medicine Market, By Care Pathway Stage
- Global Oncology Precision Medicine Market, By Technology
- Global Oncology Precision Medicine Market, By Biomarker Type
- Global Oncology Precision Medicine Market, By Sample Type
- Global Oncology Precision Medicine Market, By End User
- Global Oncology Precision Medicine Market, By Cancer Type
- Global Oncology Precision Medicine Market, By Reimbursement & Access Channel
- Global Oncology Precision Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Oncology Precision Medicine Market, By Component, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
5. Global Oncology Precision Medicine Market, By Care Pathway Stage, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Risk Assessment & Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnosis & Tumor Classification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Response Monitoring
- Resistance Emergence Detection
- Dose/Therapy Optimization
- Recurrence Surveillance / MRD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical Trial Enrolment & Matching
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Precision Medicine Market, By Technology, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
7. Global Oncology Precision Medicine Market, By Biomarker Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic Signatures / Global Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / Protein Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Methylation signatures
- MRD Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
8. Global Oncology Precision Medicine Market, By Sample Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tissue-based
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other Biofluids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Urine, saliva, CSF (indication-dependent)
- Cytology Samples
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FNA, Smears (Select Workflows)
9. Global Oncology Precision Medicine Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals & cancer centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical & biotech companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CROs / clinical trial networks
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Payers / HTA bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Oncology Precision Medicine Market, By Cancer Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare Cancers / Tumor-agnostic Segments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor-agnostic biomarker-defined populations
11. Global Oncology Precision Medicine Market, By Reimbursement & Access Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Private Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Out-of-pocket / Self-pay
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hybrid coverage models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Patient Assistance / Access Programs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical trial-funded Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
12. Global Oncology Precision Medicine Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- QIAGEN NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Foundation Medicine Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
